★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets FDA Could Approve First CRISPR Treatment in US Before Year End, Marking New Territory for Gene Editing Tech CRISPR gene editing therapies took a big step toward commercialization in the United States last week, as the FDA laid…McAlinden Research PartnersJune 13, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets More FDA Approvals Arise in Gene Editing Space, Renewed VC Rounds Begin to Ramp Up Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…McAlinden Research PartnersMay 25, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene Editing FDA Approvals for Genetic Medicines Speed Ahead Despite Recent Setbacks in Base Editing Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…McAlinden Research PartnersDecember 8, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingⓁ PharmaceuticalsMarkets Pharma Fires Up More M&A Deals in Genetic Medicine as First CRISPR Drug Moves Closer to Commercialization Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…McAlinden Research PartnersOctober 19, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets CRISPR Tech Closes in on First FDA Approval, New Treatment Methods Continue to Emerge The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…McAlinden Research PartnersSeptember 29, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets CRISPR Closing in on First US Product Launch, Latest Data Shows Treatment 100% Effective After Three Years A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…McAlinden Research PartnersJuly 11, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarkets New Genomic Breakthroughs Could Spark a CRISPR Comeback and Renewed M&A Activity in Biotech Despite a prolonged sell-off in biotech stocks, the development of genomic medicine has continued apace. For just the third time,…McAlinden Research PartnersMay 23, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Gene Editing Firms Expand Potential Treatments by Shrinking Proteins, Focusing on RNA Research Research into CRISPR gene editing technology continues to expand the amount of potential applications, while shrinking the actual size of proteins…McAlinden Research PartnersSeptember 8, 2021
★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Gene Editing May Terminate Virus Transmission, Combat Heart and Brain Disease With a Single Shot Promising developments in new gene editing trials continue to drive investor interest in the growing biotech sector. Potential advancements include the…McAlinden Research PartnersJuly 22, 2021
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & Healthcare Gene Editing Stocks Continue to Gain on New Advances in CRISPR Treatments Gene editing trials continue to heat up, as more and more labs initiate testing on humans. Genomics is increasingly popular among…McAlinden Research PartnersFebruary 4, 2021